EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 21:58 (1153 d 21:02 ago) – Posting: # 20959
Views: 5,375

Dear Osama,

❝ I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?


I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
24 visitors (0 registered, 24 guests [including 8 identified bots]).
Forum time: 19:01 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5